Poster: MM-392: Belantamab Mafodotin (Belamaf; GSK2857916) US Expanded Access Program (EAP) for Heavily Pre-Treated Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Baseline Characteristics.

Authors :: Hultcrantz, Malin
Anderson, Larry D.
Anwer, Faiz
Gasparetto, Cristina
Kocoglu, Mehmet H.
Lichtman, Eben I.
Mo, Clifton
Niesvizky, Ruben
Lewis, Eric
Li, Hong
Paul, Sofia
Petrone, Stephanie
Kaufman, Jonathan L.
Source :: Clinical Lymphoma, Myeloma & Leukemia; 2021 Supplement 1, Vol. 21, pS252-S252, 1p
Publication Year :: 2021

Full Text Access

Tools